Triumeq
Abacavir · Dolutegravir · Lamivudine
Indicated for HIV infection to support viral suppression.
- Category
- HIV Management
- Active ingredients
- Abacavir · Dolutegravir · Lamivudine
- Supply
- Rx
- Route
- Oral use
- Form
- Tablet
- Strengths
- 600/50/300mg
Triumeq details
- Condition
- HIV Infection
- Therapeutic class
- Antiretroviral Combination
- Pharmacological class
- NRTI + Integrase Inhibitor
- Minor side effects
- insomnia; headache; fatigue
- Moderate side effects
- nausea; diarrhoea; dizziness; abnormal dreams
- Dosage forms
- Tablet
- Administration route
- Oral use
- Patient summary
- indicated for HIV infection to support viral suppression.
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- ViiV Healthcare
- Onset Time
- 1–2 hours
- Duration
- 24 hours
- Storage instructions
- Store below 30°C. Keep bottle tightly closed.
- Drug interactions
- metformin; calcium supplements; iron supplements; magnesium antacids
- Age restrictions
- Use in adolescents and adults as per weight guidelines.
Contraindications
hypersensitivity to abacavir; hypersensitivity to dolutegravir; hypersensitivity to lamivudine; severe hepatic impairment
Precautions and warnings
hypersensitivity reaction (screen for HLA-B*5701 prior to use); monitor for rash; do not discontinue without medical supervision
Serious side effects
hypersensitivity reaction, requires immediate medical attention; lactic acidosis, requires immediate medical attention; hepatic toxicity, requires immediate medical attention
Mechanism of action
Triumeq combines three antiretroviral agents that inhibit HIV replication by targeting different stages of the viral life cycle. This triple action effectively maintains low viral loads and supports long-term health.
Pregnancy and breastfeeding
Pregnancy: Use only if potential benefit outweighs risk. Breastfeeding: Not recommended.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Triumeq
Triumeq combines Abacavir, Dolutegravir and Lamivudine, used in the management of HIV infection. Produced by ViiV Healthcare, the medication is provided as a single tablet in the 600/50/300mg strength. Such combination therapy simplifies treatment regimes by consolidating multiple active substances into a daily dose for those living with the virus.
Triumeq availability in Asia
Triumeq is registered across 14 markets including Singapore, Hong Kong and Thailand, with availability also in Malaysia, the Philippines and Indonesia. Access to consistent antiretroviral therapy remains a priority for expats and people living across the region. As this is a complex treatment regime, it is best used under a doctor’s care to ensure clinical oversight and long-term health.